Health and wellness company Perrigo Company plc (NYSE:PRGO)(TASE:PRGO) reported on Wednesday the receipt of the final approval from the US Food and Drug Administration (FDA) for its AB rated Abbreviated New Drug Application referencing Zovirax Cream, 5% (acyclovir cream, 5%) against herpes viruses.
The company added the generic Zovirax Cream, 5% (acyclovir cream, 5%) was developed in collaboration with Sol-Gel Technologies Ltd (NASDAQ:SLGL).
Following the US FDA's approval, the company anticipates launching Zovirax Cream, 5% (acyclovir cream, 5%) this month.
For the 12 months ending December 2018, the annual market sales were approximately USD92m as measured by IQVIA, concluded the company
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules